Skip to main content

Table 3 Subjects baseline characteristics

From: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Number of subjects

25

Median age in yrs (range)

7.4 (4.5-15.4)

Male

19 (76%)

Clinical reaction

  Respiratory

5 (20%)

  Gastro-intestinal

13 (52%)

  Epinephrine

1 (4%)

Number of foods dosed

  2

7 (28%)

  3

4 (16%)

  4

7 (28%)

  5

7 (28%)

Peanut baseline allergy test (if included in mix) (median and range)

  SPT in mm

13 (3.5-26)

  Specific IgE in kUa/L

31 (1–192)

  Lowest amount triggering reaction in DBPCFC in mg protein

15.5 (1.6-100)

Highest baseline allergy test (median and range)

  SPT in mm

17 (6–29.5)

  Specific IgE in kUa/L

66 (2–256)

  Lowest amount triggering reaction in DBPCFC in mg protein

6 (0.1-100)

Total IgE in kuA/L (median and range)

645 (67–1829)